322 related articles for article (PubMed ID: 9592984)
1. Hemostasis and blood requirements in orthotopic liver transplantation with and without high-dose aprotinin.
Llamas P; Cabrera R; Gómez-Arnau J; Fernández MN
Haematologica; 1998 Apr; 83(4):338-46. PubMed ID: 9592984
[TBL] [Abstract][Full Text] [Related]
2. Fibrinolytic activity during orthotopic liver transplantation with and without aprotinin.
Segal HC; Hunt BJ; Cottam S; Downing A; Beard C; Francis JL; Potter D; Tan KC
Transplantation; 1994 Dec; 58(12):1356-60. PubMed ID: 7528949
[TBL] [Abstract][Full Text] [Related]
3. Plasma MMP-2 and MMP-9 and their inhibitors TIMP-1 and TIMP-2 during human orthotopic liver transplantation. The effect of aprotinin and the relation to ischemia/reperfusion injury.
Kuyvenhoven JP; Molenaar IQ; Verspaget HW; Veldman MG; Palareti G; Legnani C; Moolenburgh SE; Terpstra OT; Lamers CB; van Hoek B; Porte RJ
Thromb Haemost; 2004 Mar; 91(3):506-13. PubMed ID: 14983226
[TBL] [Abstract][Full Text] [Related]
4. Aprotinin in orthotopic liver transplantation: evidence for a prohemostatic, but not a prothrombotic, effect.
Molenaar IQ; Legnani C; Groenland TH; Palareti G; Begliomini B; Terpstra OT; Porte RJ
Liver Transpl; 2001 Oct; 7(10):896-903. PubMed ID: 11679989
[TBL] [Abstract][Full Text] [Related]
5. Changes in the contact system during orthotopic liver transplantation with and without aprotinin.
Segal HC; Hunt BJ; Cottam S; Beard C; Francis JL; Potter D; Tan KC
Transplantation; 1995 Feb; 59(3):366-70. PubMed ID: 7532878
[TBL] [Abstract][Full Text] [Related]
6. The effect of two different doses of aprotinin on hemostasis in cardiopulmonary bypass surgery: similar transfusion requirements and blood loss.
Santamaría A; Mateo J; Oliver A; Litvan H; Murillo J; Souto JC; Fontcuberta J
Haematologica; 2000 Dec; 85(12):1277-84. PubMed ID: 11114135
[TBL] [Abstract][Full Text] [Related]
7. Evolution of urokinase-type plasminogen activator (u-PA) and tissue-type plasminogen activator (t-PA) in orthotopic liver transplantation (OLT).
Himmelreich G; Dooijewaard G; Breinl P; Bechstein WO; Neuhaus P; Kluft C; Riess H
Thromb Haemost; 1993 Jan; 69(1):56-9. PubMed ID: 8446939
[TBL] [Abstract][Full Text] [Related]
8. [Reduction of the need for blood derivatives in liver transplantation using aprotinin].
Monedero P; Páramo JA; Carrascosa F; Herrero JI; Hidalgo F; Iribarren MJ; García-Pedrajas F
Rev Esp Anestesiol Reanim; 1995 Mar; 42(3):82-6. PubMed ID: 7539932
[TBL] [Abstract][Full Text] [Related]
9. Low doses of aprotinin in aortocoronary bypass surgery--advantages and disadvantages.
Golański R; Golański J; Chizyński K; Iwaszkiewicz A; Zasłonka J; Pietrucha T; Chrul S; Watała C
Med Sci Monit; 2000; 6(4):722-8. PubMed ID: 11208399
[TBL] [Abstract][Full Text] [Related]
10. The prophylactic use of tranexamic acid and aprotinin in orthotopic liver transplantation: a comparative study.
Dalmau A; Sabaté A; Koo M; Bartolomé C; Rafecas A; Figueras J; Jaurrieta E
Liver Transpl; 2004 Feb; 10(2):279-84. PubMed ID: 14762867
[TBL] [Abstract][Full Text] [Related]
11. Aprotinin reduces red blood cell transfusion in orthotopic liver transplantation: a prospective, randomized, double-blind study.
Findlay JY; Rettke SR; Ereth MH; Plevak DJ; Krom RA; Kufner RP
Liver Transpl; 2001 Sep; 7(9):802-7. PubMed ID: 11552215
[TBL] [Abstract][Full Text] [Related]
12. Comparison of the effects of aprotinin and tranexamic acid on blood loss and red blood cell transfusion requirements during the late stages of liver transplantation.
Ickx BE; van der Linden PJ; Melot C; Wijns W; de Pauw L; Vandestadt J; Hut F; Pradier O
Transfusion; 2006 Apr; 46(4):595-605. PubMed ID: 16584436
[TBL] [Abstract][Full Text] [Related]
13. Tranexamic acid and aprotinin in primary cardiac operations: an analysis of 220 cardiac surgical patients treated with tranexamic acid or aprotinin.
Dietrich W; Spannagl M; Boehm J; Hauner K; Braun S; Schuster T; Busley R
Anesth Analg; 2008 Nov; 107(5):1469-78. PubMed ID: 18931201
[TBL] [Abstract][Full Text] [Related]
14. Transfusion requirements are correlated with the degree of proteolysis of von Willebrand factor during orthotopic liver transplantation.
Lattuada A; Mannucci PM; Chen C; Legnani C; Palareti G
Thromb Haemost; 1997 Aug; 78(2):813-9. PubMed ID: 9268177
[TBL] [Abstract][Full Text] [Related]
15. Hemostatic variation during perioperative period of orthotopic liver transplantation without venovenous bypass.
Wang Y; Liu Y; Han R; Zhu Z; Zhang Y; Wang X; Wang L; Shen Z
Thromb Res; 2008; 122(2):161-6. PubMed ID: 18048090
[TBL] [Abstract][Full Text] [Related]
16. Decreasing blood product requirements after orthotopic liver transplantation.
Gordon PC; James MF; Spearman CW; Millar AJ; Kahn D
S Afr J Surg; 2002 May; 40(2):46-8. PubMed ID: 12162230
[TBL] [Abstract][Full Text] [Related]
17. Aprotinin efficacy on intraoperative bleeding and transfusion requirements in orthotopic liver transplantation.
Patrassi GM; Viero M; Sartori MT; De Silvestro G; Rossaro L; Burra P; Nolli ML; Piccinni P; Bassi N
Transfusion; 1994 Jun; 34(6):507-11. PubMed ID: 7517586
[TBL] [Abstract][Full Text] [Related]
18. Postoperative hemostasis and fibrinolysis in patients undergoing cardiopulmonary bypass with or without aprotinin therapy.
Lu H; Du Buit C; Soria J; Touchot B; Chollet B; Commin PL; Conseiller C; Echter E; Soria C
Thromb Haemost; 1994 Sep; 72(3):438-43. PubMed ID: 7531877
[TBL] [Abstract][Full Text] [Related]
19. The impact of aprotinin on blood loss and blood transfusion in off-pump coronary artery bypass grafting.
Bittner HB; Lemke J; Lange M; Rastan A; Mohr FW
Ann Thorac Surg; 2008 May; 85(5):1662-8. PubMed ID: 18442562
[TBL] [Abstract][Full Text] [Related]
20. Influence of prostaglandin E1 infusion on hemostasis in orthotopic liver transplantation.
Himmelreich G; Hundt K; Bechstein WO; Rossaint R; Neuhaus P; Riess H
Semin Thromb Hemost; 1993; 19(3):273-8. PubMed ID: 7689752
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
